Clinical Evidence

ClinicalEVIDENCE Newsletter

Newsletter 5/2023

Delve deeper into the insights provided by the recent PREEMPT-HF trial and the posters featuring findings from two HeartLogic studies presented at the HFSA 2023 Congress.

Newsletter 4/2023

Delve into the main takeaways from the recent HeartLogicTM and Remote Monitoring publications, and explore three abstracts related to HeartLogic that were showcased at the ESC Congress 2023.

Newsletter 3/2023

Go through some key messages from the latest publications on HeartLogicTM algorithm as we provide insights into its clinical benefits and performance.

Newsletter 2/2023

Explore the latest research on HeartLogicTM, a cutting-edge algorithm that effectively predicts all-cause mortality, ventricular arrhythmias, and atrial fibrillation events in heart failure patients.

Newsletter 1/2023

Discover the latest advancements in remote monitoring of cardiac devices and its impact on long-term mortality.

HEARTLOGIC™ Newsletter 2020-2022

Have a look at our previous newsletters about HeartLogic from Boston Scientific

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.